Top

Published in:

01-09-2009 | Original Paper

Expression of EphA2 and E-cadherin in Gastric Cancer: Correlated with Tumor Progression and Lymphogenous Metastasis

Authors: Weijie Yuan, Zhikang Chen, Shaobin Wu, Jie Ge, Shi Chang, Xianwei Wang, Jingxiang Chen, Zihua Chen

Published in: Pathology & Oncology Research | Issue 3/2009

Abstract

In this study, gastric cancer progression was correlated with the over-expression of erythropoietin-producing hepatocellular (Eph)A2 receptor and down-expression of epithelial cadherin (E-cadherin). Immunohistochemistry of EphA2 and E-cadherin were performed on these tumor samples from 165 primary lesions of gastric cancer. The results showed that expression of EphA2 was obviously increased in gastric cancer tissues (P < 0.01), which was positively correlated with the depth of cancer invasion, tumor-node-metastasis (TNM) stage and lymph node metastasis (P < 0.05). Meanwhile, the expression of E-cadherin was significantly reduced (P < 0.01), which was negatively correlated with the depth of cancer invasion, grade of tumor differentiation, TNM stage and lymph node metastasis (P < 0.05). The correlation between EphA2 and E-cadherin expression was negative (r = −0.198, P = 0.011). In conclusion, either the over-expression of EphA2 or the down-expression of E-cadherin is correlated with cancer progression and lymphogenous metastasis in gastric cancer, suggesting that both of them may play an important role in tumor progression and metastasis.

Catalano V, Labianca R, Beretta GD et al (2005) Gastric cancer. Crit Rev Oncol Hematol 54:209–241CrossRefPubMed

Dicken BJ, Bigam DL, Cass C et al (2005) Gastric adenocarcinoma: review and considerations for future directions. Ann Surg 241:27–39PubMed

Sulman EP, Tang XX, Allen C et al (1997) ECK, a human EPH-related gene, maps to 1p36.1, a common region of alteration in human cancers. Genomics 40:371–374CrossRefPubMed

Walker-Daniels J, Hess AR, Hendrix MJC et al (2003) Differential regulation of EphA2 in normal and malignant cells. Am J Pathol 162:1037–1042PubMed

Miyazaki T, Kato H, Fukuchi M et al (2003) EphA2 overexpression correlates with poor prognosis in esophageal squamous cell carcinoma. Int J Cancer 103:657–663CrossRefPubMed

Zeng G, Hu Z, Kinch MS et al (2003) High-level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia. Am J Pathol 163:2271–2276PubMed

Kinch MS, Moore MB, Harpole DH et al (2003) Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. Clin Cancer Res 9:613–618PubMed

Han L, Dong Z, Qiao Y et al (2005) The clinical significance of EphA2 and Ephrin A-1 in epithelial ovarian carcinomas. Gynecol Oncol 99:278–286CrossRefPubMed

Abraham S, Knapp DW, Cheng L et al (2006) Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder. Clin Cancer Res 12:353–360CrossRefPubMed

10.

Bussemakers MJ, van Bokhoven A, Mees SG et al (1993) Molecular cloning and characterization of the human E-cadherin cDNA. Mol Biol Rep 17:123–128CrossRefPubMed

11.

Takeichi M (1993) Cadherins in cancer: implications for invasion and metastasis. Curr Opin Cell Biol 5:806–811CrossRefPubMed

12.

Chen H, Paradies NE, Fedor-Chaiken M et al (1997) E-cadherin mediates adhesion and suppresses cell motility via distinct mechanisms. J Cell Sci 110:345–356PubMed

13.

Hazan RB, Qiao R, Keren R et al (2004) Cadherin switch in tumor progression. Ann NY Acad Sci 1014:155–163CrossRefPubMed

14.

Zantek ND, Azimi M, Fedor-Chaiken M et al (1999) E-cadherin regulates the function of the EphA2 receptor tyrosine kinase. Cell Growth Differ 10:629–638PubMed

15.

Thaker PH, Deavers M, Celestino J et al (2004) EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res 10:5145–5150CrossRefPubMed

16.

Lin YG, Han LY, Kamat AA et al (2007) EphA2 overexpression is associated with angiogenesis in ovarian cancer. Cancer 109:332–340CrossRefPubMed

17.

Shiozaki H, Tahara H, Oka H et al (1991) Expression of immunoreactive E-cadherin adhesion molecule in human cancer. Am J Pathol 139:17–23PubMed

18.

Jawhari A, Jordan S, Poole S et al (1997) Abnormal immunoreactivity of the E-cadherin-catenin complex in gastric carcinoma: relationship with patient survival. Gastroenterology 112:46–54CrossRefPubMed

19.

Zhou Y, Ran J, Tang C (2007) Effect of celecoxib on E-cadherin, VEGF, Microvessel density and apoptosis in gastric cancer. Cancer Biol Ther 6:269–275CrossRefPubMed

20.

Sobin LH, Wittekind CH (eds) (1997) TNM Classification of Malignant Tumors, 5th edn. Wiley, New York

21.

Ogawa K, Pasqualini R, Lindberg RA et al (2000) The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene 19:6043–6052CrossRefPubMed

22.

Zelinski DP, Zantek ND, Stewart JC et al (2001) EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res 61:2301–2306PubMed

23.

Fang WB, Brantley-Sieders DM, Parker MA et al (2005) A kinase-dependent role for EphA2 receptor in promoting tumor growth and metastasis. Oncogene 24:7859–7868CrossRefPubMed

24.

Lu C, Shahzad MM, Wang H et al (2008) EphA2 overexpression promotes ovarian cancer growth. Cancer Biol Ther 7:1–6CrossRef

25.

Zantek ND, Walker-Daniels J, Stewart J et al (2001) MCF-10A-NeoST: a new cell system for studying cell-ECM and cell-cell interactions in breast cancer. Clin Cancer Res 7:3640–3648PubMed

26.

Kinch MS, Carles-Kinch K (2003) Overexpression and functional alterations of the EphA2 tyrosine kinase in cancer. Clin Exp Metastasis 20:59–68CrossRefPubMed

27.

Kikawa KD, Vidale DR, Van Etten RL et al (2002) Regulation of the EphA2 kinase by the low molecular weight tyrosine phosphatase induces transformation. J Biol Chem 277:39274–39279CrossRefPubMed

28.

Parri M, Buricchi F, Taddei ML et al (2005) EphrinA1 repulsive response is regulated by an EphA2 tyrosine phosphatase. J Biol Chem 280:34008–34018CrossRefPubMed

29.

Chen HC, Chu RY, Hsu PN et al (2003) Loss of E-cadherin expression correlates with poor differentiation and invasion into adjacent organs in gastric adenocarcinomas. Cancer Lett 201:97–106CrossRefPubMed

30.

Lee KH, Shin SJ, Kim KO et al (2006) Relationship between E-cadherin, matrix metalloproteinase-7 gene expression and clinicopathological features in gastric carcinoma. Oncol Rep 16:823–830PubMed

31.

Guilford PJ, Hopkins JB, Grady WM et al (1999) E-cadherin germline mutations define an inherited cancer syndrome dominated by diffuse gastric cancer. Hum Mutat 14:249–255CrossRefPubMed

32.

Tamura G, Yin J, Wang S et al (2000) E-Cadherin gene promoter hypermethylation in primary human gastric carcinomas. J Natl Cancer Inst 92:569–573CrossRefPubMed

33.

Koizume S, Tachibana K, Sekiya T et al (2002) Heterogeneity in the modification and involvement of chromatin components of the CpG island of the silenced human CDH1 gene in cancer cells. Nucleic Acids Res 30:4770–4780CrossRefPubMed

34.

Catimel B, Layton M, Church N et al (2006) In situ phosphorylation of immobilized receptors on biosensor surfaces: application to E-cadherin/beta-catenin interactions. Anal Biochem 357:277–288CrossRefPubMed

35.

Noë V, Fingleton B, Jacobs K et al (2001) Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J Cell Sci 114:111–118PubMed

36.

Rios-Doria J, Day KC, Kuefer R et al (2003) The role of calpain in the proteolytic cleavage of E-cadherin in prostate and mammary epithelial cells. J Biol Chem 278:1372–1379CrossRefPubMed

37.

Saito T, Masuda N, Miyazaki T et al (2004) Expression of EphA2 and E-cadherin in colorectal cancer: correlation with cancer metastasis. Oncol Rep 11:605–611PubMed

38.

Orsulic S, Kemler R (2000) Expression of Eph receptors and ephrins is differentially regulated by E-cadherin. J Cell Sci 113:1793–1802PubMed

Title: Expression of EphA2 and E-cadherin in Gastric Cancer: Correlated with Tumor Progression and Lymphogenous Metastasis
Authors: Weijie Yuan
Zhikang Chen
Shaobin Wu
Jie Ge
Shi Chang
Xianwei Wang
Jingxiang Chen
Zihua Chen
Publication date: 01-09-2009
Publisher: Springer Netherlands
Published in: Pathology & Oncology Research / Issue 3/2009
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-008-9132-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2009

Hematopoietic- and Neurologic-Expressed Sequence 1 Expression in the Murine GL261 and High-Grade Human Gliomas

Composite Carcinoma of the Stomach Associated with Sarcoid-Like Granulomas

Prognostic Significance of Cell Proliferation and Apoptosis-Regulating Proteins in Epstein-Barr Virus Positive and Negative Pediatric Non-Hodgkin’s Lymphoma

Platinum-Based Chemotherapy in Lung Cancer Affects the Expression of Certain Biomarkers Including ERCC1

Short or Long Survival in Multiple Myeloma. A Simple Method for Determining the Prognosis

Hypoxia Generates a More Invasive Phenotype of Tumour Cells: An In Vivo Experimental Setup Based on the Chorioallantoic Membrane

Keynote webinar | Spotlight on antibody–drug conjugates in cancer